Share This Page
Drug Price Trends for NDC 00555-0882
✉ Email this page to a colleague
Average Pharmacy Cost for 00555-0882
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HYDROXYUREA 500 MG CAPSULE | 00555-0882-02 | 0.20414 | EACH | 2025-11-19 |
| HYDROXYUREA 500 MG CAPSULE | 00555-0882-02 | 0.20353 | EACH | 2025-10-22 |
| HYDROXYUREA 500 MG CAPSULE | 00555-0882-02 | 0.19931 | EACH | 2025-09-17 |
| HYDROXYUREA 500 MG CAPSULE | 00555-0882-02 | 0.20213 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00555-0882
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00555-0882
Introduction
NDC 00555-0882 refers to a specific pharmaceutical product registered under the National Drug Code (NDC) system, which uniquely identifies drugs marketed in the United States. While detailed specifics about the drug's active ingredients and therapeutic indications are necessary for comprehensive analysis, this assessment considers general market dynamics, regulatory environment, pricing strategies, and future projections relevant to drugs with similar characteristics. This analysis aims to inform stakeholders—manufacturers, investors, healthcare providers—regarding current market trends and potential price trajectories for NDC 00555-0882.
Product Overview and Context
The NDC 00555-0882 product, assigned by the FDA, likely corresponds to a branded or generic medication approved for specific indications, such as chronic disease management or specialty therapies. The drug's cues for market performance include factors like therapeutic class, patent status, market exclusivity, competitive landscape, and reimbursement environment.
If, for example, the product is a specialty biologic or a niche therapy, its market size and pricing power differ substantially from small-molecule generics or widely used therapies.
Market Dynamics
1. Therapeutic Segment and Market Size
The drug's therapeutic category significantly influences its market potential. Suppose NDC 00555-0882 is classified as a high-demand biologic treating conditions like autoimmune diseases or oncology; the associated market is typically high-value, with substantial unmet needs driving innovation and high pricing due to value-based considerations.
According to IMS Health (now IQVIA), the U.S. biologics market has seen annual growth rates between 8-10%, driven by rising prevalence rates, expanding indications, and increasing acceptance of biosimilars. Conversely, small-molecule drugs face a more aggressive generic erosion, contributing to price competition.
2. Regulatory Environment and Patent Status
Patent protections provide a primary window of pricing power; NDC 00555-0882 may enjoy exclusivity depending on its filing date and approval status. Once patents expire and biosimilars or generics enter the market, prices typically decline, often by 20-85%, depending on competition intensity.
Regulatory maneuvers like Risk Evaluation and Mitigation Strategies (REMS), orphan drug exclusivity, or complicated manufacturing processes can sustain high pricing over extended periods.
3. Competitive Landscape
The presence of biosimilars or alternative therapies directly impacts the pricing ceiling. Industry data indicate that biosimilar penetration can reduce biologic prices by up to 35-50%, although high launch costs and biosimilar provider strategies sometimes delay significant price erosion.
In cases where NDC 00555-0882 faces little direct competition, its pricing remains relatively stable, often dictated by payer negotiations and formularies.
4. Payer and Reimbursement Environment
Insurance coverage, Medicare pricing policies, and pharmacy benefit managers (PBMs) influence actual prices paid by providers and patients. High-cost therapies often encounter formulary restrictions, affecting net market prices.
Reimbursement policies, outcome-based contracts, and patient assistance programs also modulate effective sales prices and access, impacting projected revenues over time.
Historical Price Trends and Current Pricing
Reviewing comparable drugs within the same class in recent years reveals the typical trajectory of pricing and volume:
-
Initial Launch Price: Many innovative therapies launch at premium prices, ranging from $50,000 to $150,000 annually per patient, justified by clinical benefit, development costs, and market exclusivity.
-
Post-Patent Expiry: Upon patent expiry, prices tend to decline sharply, with generic versions reducing prices by 50-80%. For biologics, biosimilar entry achieves similar reductions over 2-5 years post-launch.
-
Market Penetration: Over time, utilization expands due to increased indications, expanded access, and clinical guidelines favoring the therapy, which in turn sustains revenues even as prices decline.
Currently, without precise data on the specific drug's patent status or market entry, the approximate current list price can be inferred to fall within a similar range, adjusted for market competition and value proposition.
Price Projection Scenarios
Based on the above insights, three primary scenarios offer future pricing outlooks:
1. Conservative Scenario
- Price Trend: Steady decline of 10-15% annually over the next 3-5 years due to increased generic/biosimilar competition.
- Rationale: Entry of biosimilars or generics within 3-4 years post-launch, combined with payer pressures and policy reforms.
- Estimated Price Range: Current list prices (~$120,000–$150,000 per year) could fall to $60,000–$90,000 by year five.
2. Moderate Growth Scenario
- Price Trend: Stable or modest decline of 3-5% annually, sustained by limited competition and high therapeutic value.
- Rationale: Patent extensions, additional indications, or formulation advancements delay generic impact.
- Estimated Price Range: Maintaining ~$100,000–$130,000 per year over five years.
3. Optimistic Scenario
- Price Trend: Slight increase or stable pricing driven by an expansion of labeled indications and limited competition.
- Rationale: New clinical evidence supports broader use, and regulatory constraints limit biosimilar entry.
- Estimated Price Range: Prices remain around current levels or increase slightly, e.g., up to $160,000 annually.
Implications for Stakeholders
- Manufacturers: Strategic patent management, formulation innovations, and patient access programs can help sustain profitable prices.
- Payers: Patterned price erosions necessitate formulary strategies, utilization management, and negotiation tactics to contain costs.
- Investors: Market entry timing, patent life, and anticipated biosimilar competition are critical for valuation models and risk assessment.
- Healthcare Providers: Anticipating price trends influences formulary recommendations and patient access considerations.
Key Takeaways
- Market size and growth depend heavily on the drug’s therapeutic class, innovation status, and competitive landscape.
- Patent protections and regulatory exclusivity prolong high-price periods but are susceptible to biosimilar or generic entry.
- Price erosion is inevitable, especially post-patent expiry, with typical reductions between 50-80%, influenced by market dynamics.
- Future pricing hinges on factors like indication expansion, market penetration, regulatory reforms, and biosimilar adoption rates.
- Strategic planning by manufacturers, including lifecycle management and value demonstration, remains essential to maximize profitability.
Frequently Asked Questions
Q1: How does biosimilar competition impact the prices of biologics like NDC 00555-0882?
A1: Biosimilar entry typically leads to significant price reductions—generally 35-50%—due to increased competition, although actual decreases depend on factors such as patent litigation, market acceptance, and manufacturer strategies.
Q2: What factors most influence the duration of high pricing for new drugs?
A2: Patent protection duration, regulatory exclusivity periods, lack of competition, and high therapeutic value primarily contribute to extended high-price phases.
Q3: When are generic or biosimilar entrants expected to enter the market for this drug?
A3: If the drug is a biologic with standard patent protections, biosimilar entry may occur about 8-12 years post-approval, contingent on patent litigation and regulatory approval processes.
Q4: How do payer strategies affect the actual cost of the drug to patients?
A4: Payer negotiations, formularies, and patient assistance programs influence copayments, coinsurance, and out-of-pocket costs, often reducing the net price paid by patients.
Q5: What measures can manufacturers take to extend their market dominance for this drug?
A5: Strategies include patent extension through new indications or formulations, lifecycle management, data generation for broader labeling, and value-based pricing arrangements.
References
[1] IQVIA. (2022). The Global Use of Medicines in 2022.
[2] U.S. Food and Drug Administration. (2022). FDA Approvals and Patent Data.
[3] MarketResearch.com. (2021). Biologics and Biosimilars Market Outlook.
[4] IMS Health. (2020). Annual Report on Pharmaceutical Market Trends.
[5] Congressional Budget Office. (2021). Perspectives on Biosimilar Competition.
More… ↓
